{"id":1176423,"date":"2021-12-27T13:22:50","date_gmt":"2021-12-27T12:22:50","guid":{"rendered":"https:\/\/frezzapartners.com\/?p=1176423"},"modified":"2021-12-27T13:24:14","modified_gmt":"2021-12-27T12:24:14","slug":"sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/frezzapartners.com\/en\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\/","title":{"rendered":"Sanofi acquisisce la pipeline di immuno-oncologia di Amunix Pharmaceuticals"},"content":{"rendered":"<p>photo by Cytonn Photography<\/p>\n<p>&nbsp;<\/p>\n<p>Sanofi <a href=\"https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2021\/2021-12-21-05-30-00-2355740\">ha annunciato<\/a> di aver stipulato un accordo per l&#8217;acquisizione di Amunix Pharmaceuticals, Inc., una societ\u00e0 di immuno-oncologia che sfrutta la sua XTEN\u00ae\u00a0 clinicamente convalidata e l&#8217;innovativa piattaforma tecnologica di mascheratura rilasciabile con proteasi universale, Pro-XTENTM, per scoprire e sviluppare &#8220;T-cell engagers &#8221; trasformative (TCE) e terapie con citochine per i pazienti con cancro.<br \/>\nL&#8217;acquisizione supporta gli sforzi di Sanofi per accelerare ed espandere i suoi contributi ai farmaci innovativi per i pazienti oncologici, con circa 20 molecole attualmente in fase di sviluppo.<\/p>\n<p>&#8220;Questa acquisizione dimostra il nostro costante impegno a investire in promettenti piattaforme di ricerca e scoperta&#8221;, ha affermato John Reed, M.D., Ph.D., Global Head of Research &amp; Development, Sanofi. \u201cLa piattaforma tecnologica Amunix utilizza un approccio biologico intelligente di nuova generazione per fornire farmaci su misura in modo che diventino attivi solo nei tessuti tumorali risparmiando i tessuti normali, offrendo cos\u00ec la promessa di opzioni di trattamento pi\u00f9 efficaci e pi\u00f9 sicure per i malati di cancro. Siamo entusiasti di far avanzare rapidamente la promettente pipeline di Amunix e di combinare i loro innovativi farmaci candidati con molecole complementari nel portafoglio di immuno-oncologia di Sanofi\u201d.<\/p>\n<p>&nbsp;<\/p>\n<p>Per leggere il comunicato stampa ufficiale clicca <a href=\"https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2021\/2021-12-21-05-30-00-2355740\">qui<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>photo by Cytonn Photography &nbsp; Sanofi ha annunciato di aver stipulato un accordo per l&#8217;acquisizione di Amunix Pharmaceuticals, Inc., una societ\u00e0 di immuno-oncologia che sfrutta la sua XTEN\u00ae\u00a0 clinicamente convalidata e l&#8217;innovativa piattaforma tecnologica di mascheratura rilasciabile con proteasi universale, Pro-XTENTM, per scoprire e sviluppare &#8220;T-cell engagers &#8221; trasformative (TCE) e terapie con citochine per i pazienti con cancro. L&#8217;acquisizione supporta gli sforzi di Sanofi per accelerare ed espandere i suoi contributi ai farmaci innovativi per i pazienti oncologici, con&#8230;<\/p>\n","protected":false},"author":297440,"featured_media":1176424,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[141],"tags":[3378,3379,2625],"class_list":["post-1176423","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-acquisitions","tag-amunix","tag-sanofi"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sanofi acquisisce la pipeline di immuno-oncologia di Amunix Pharmaceuticals - Frezza Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/frezzapartners.com\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi acquisisce la pipeline di immuno-oncologia di Amunix Pharmaceuticals - Frezza Partners\" \/>\n<meta property=\"og:description\" content=\"photo by Cytonn Photography &nbsp; Sanofi ha annunciato di aver stipulato un accordo per l&#8217;acquisizione di Amunix Pharmaceuticals, Inc., una societ\u00e0 di immuno-oncologia che sfrutta la sua XTEN\u00ae\u00a0 clinicamente convalidata e l&#8217;innovativa piattaforma tecnologica di mascheratura rilasciabile con proteasi universale, Pro-XTENTM, per scoprire e sviluppare &#8220;T-cell engagers &#8221; trasformative (TCE) e terapie con citochine per i pazienti con cancro. L&#8217;acquisizione supporta gli sforzi di Sanofi per accelerare ed espandere i suoi contributi ai farmaci innovativi per i pazienti oncologici, con...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/frezzapartners.com\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Frezza Partners\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-27T12:22:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-27T12:24:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/frezzapartners.com\/wp-content\/uploads\/2021\/12\/cytonn-photography-GJao3ZTX9gU-unsplash-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1709\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frezza Partners\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frezza Partners\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\\\/\"},\"author\":{\"name\":\"Frezza Partners\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"headline\":\"Sanofi acquisisce la pipeline di immuno-oncologia di Amunix Pharmaceuticals\",\"datePublished\":\"2021-12-27T12:22:50+00:00\",\"dateModified\":\"2021-12-27T12:24:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\\\/\"},\"wordCount\":214,\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2021\\\/12\\\/cytonn-photography-GJao3ZTX9gU-unsplash-scaled.jpg\",\"keywords\":[\"acquisitions\",\"Amunix\",\"sanofi\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\\\/\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\\\/\",\"name\":\"Sanofi acquisisce la pipeline di immuno-oncologia di Amunix Pharmaceuticals - Frezza Partners\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2021\\\/12\\\/cytonn-photography-GJao3ZTX9gU-unsplash-scaled.jpg\",\"datePublished\":\"2021-12-27T12:22:50+00:00\",\"dateModified\":\"2021-12-27T12:24:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/frezzapartners.com\\\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\\\/#primaryimage\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2021\\\/12\\\/cytonn-photography-GJao3ZTX9gU-unsplash-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2021\\\/12\\\/cytonn-photography-GJao3ZTX9gU-unsplash-scaled.jpg\",\"width\":2560,\"height\":1709},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/frezzapartners.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi acquisisce la pipeline di immuno-oncologia di Amunix Pharmaceuticals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/\",\"name\":\"Frezza Partners\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/frezzapartners.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\",\"name\":\"Frezza Partners\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/en\\\/author\\\/fr3zz4partn3rs\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sanofi acquisisce la pipeline di immuno-oncologia di Amunix Pharmaceuticals - Frezza Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/frezzapartners.com\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\/","og_locale":"en_US","og_type":"article","og_title":"Sanofi acquisisce la pipeline di immuno-oncologia di Amunix Pharmaceuticals - Frezza Partners","og_description":"photo by Cytonn Photography &nbsp; Sanofi ha annunciato di aver stipulato un accordo per l&#8217;acquisizione di Amunix Pharmaceuticals, Inc., una societ\u00e0 di immuno-oncologia che sfrutta la sua XTEN\u00ae\u00a0 clinicamente convalidata e l&#8217;innovativa piattaforma tecnologica di mascheratura rilasciabile con proteasi universale, Pro-XTENTM, per scoprire e sviluppare &#8220;T-cell engagers &#8221; trasformative (TCE) e terapie con citochine per i pazienti con cancro. L&#8217;acquisizione supporta gli sforzi di Sanofi per accelerare ed espandere i suoi contributi ai farmaci innovativi per i pazienti oncologici, con...","og_url":"https:\/\/frezzapartners.com\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\/","og_site_name":"Frezza Partners","article_published_time":"2021-12-27T12:22:50+00:00","article_modified_time":"2021-12-27T12:24:14+00:00","og_image":[{"width":2560,"height":1709,"url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2021\/12\/cytonn-photography-GJao3ZTX9gU-unsplash-scaled.jpg","type":"image\/jpeg"}],"author":"Frezza Partners","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Frezza Partners","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/frezzapartners.com\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/frezzapartners.com\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\/"},"author":{"name":"Frezza Partners","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"headline":"Sanofi acquisisce la pipeline di immuno-oncologia di Amunix Pharmaceuticals","datePublished":"2021-12-27T12:22:50+00:00","dateModified":"2021-12-27T12:24:14+00:00","mainEntityOfPage":{"@id":"https:\/\/frezzapartners.com\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\/"},"wordCount":214,"image":{"@id":"https:\/\/frezzapartners.com\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2021\/12\/cytonn-photography-GJao3ZTX9gU-unsplash-scaled.jpg","keywords":["acquisitions","Amunix","sanofi"],"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/frezzapartners.com\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\/","url":"https:\/\/frezzapartners.com\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\/","name":"Sanofi acquisisce la pipeline di immuno-oncologia di Amunix Pharmaceuticals - Frezza Partners","isPartOf":{"@id":"https:\/\/frezzapartners.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/frezzapartners.com\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/frezzapartners.com\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2021\/12\/cytonn-photography-GJao3ZTX9gU-unsplash-scaled.jpg","datePublished":"2021-12-27T12:22:50+00:00","dateModified":"2021-12-27T12:24:14+00:00","author":{"@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"breadcrumb":{"@id":"https:\/\/frezzapartners.com\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/frezzapartners.com\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/frezzapartners.com\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\/#primaryimage","url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2021\/12\/cytonn-photography-GJao3ZTX9gU-unsplash-scaled.jpg","contentUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2021\/12\/cytonn-photography-GJao3ZTX9gU-unsplash-scaled.jpg","width":2560,"height":1709},{"@type":"BreadcrumbList","@id":"https:\/\/frezzapartners.com\/sanofi-acquisisce-la-pipeline-di-immuno-oncologia-amunix-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/frezzapartners.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi acquisisce la pipeline di immuno-oncologia di Amunix Pharmaceuticals"}]},{"@type":"WebSite","@id":"https:\/\/frezzapartners.com\/#website","url":"https:\/\/frezzapartners.com\/","name":"Frezza Partners","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/frezzapartners.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0","name":"Frezza Partners","url":"https:\/\/frezzapartners.com\/en\/author\/fr3zz4partn3rs\/"}]}},"_links":{"self":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/1176423","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/users\/297440"}],"replies":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/comments?post=1176423"}],"version-history":[{"count":0,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/1176423\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media\/1176424"}],"wp:attachment":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media?parent=1176423"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/categories?post=1176423"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/tags?post=1176423"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}